Sugarman-Brozan says FDA is neglecting enforcement

Prescription Access Litigation project director Alex Sugarman-Brozan told the Third Annual FDA Regulatory Symposium at Harvard in August that the agency is neglecting to enforce regulations on DTC advertising and needs to crack down on drug companies with more and earlier enforcement letters and hefty fines on offending companies, per pending regs.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions